Synaffix Licenses CliCr Chemistry from Cristal Therapeutics

Synaffix obtains exclusive rights to the CliCr technology, to combine with its proprietary ADC platform technology CliCr further expands the repertoire of payloads suitable for conjugation by

Related Keywords

Amsterdam , Noord Holland , Netherlands , Innovent Biologics , Kostenloser Wertpapierhandel , Cristianne Rijcken , Platform Technology , Cristal Therapeutics , Chief Scientific Officer , Noble Prize , Mersana Therapeutics , Shanghai Miracogen , Kyowa Kirin , Biogeneration Ventures , Synaffix , Licenses , Licr , Chemistry , Rom , Christal , Herapeutics , Fortify , Pest , Glass , Technology , Offering ,